Berberine side effects: what studies and NCCIH report

Share

Email article

The side effects reported most often for berberine are digestive. NCCIH, part of the US National Institutes of Health, states: "Some side effects of berberine have been reported in research studies, primarily gastrointestinal symptoms such as nausea, abdominal pain, bloating, constipation, or diarrhea."[1] Yin and colleagues reported temporary digestive side effects in 20 of 58 participants (34.5%) who received berberine across the two parts of their pilot study; 14 needed a dose reduction.[2]

What the studies reported

SourceWho was studiedWhat was reported
Umbrella review of 11 meta-analyses, 2023Meta-analyses published 2013–2022Common side effects were digestive, such as constipation and diarrhea[3]
Meta-analysis, 2022, type 2 diabetesAdverse events: 14 studies, 1,321 people; low blood sugar: 2 trials with events, 186 peopleTotal adverse events were not higher with berberine (relative risk 0.73); low blood sugar showed no significant difference (relative risk 0.48, 95% CI 0.21–1.08), with very low certainty[4]
Meta-analysis of 10 trials, 2024811 people with fatty liver diseaseOnly mild digestive adverse events were reported, in trials lasting 7–24 weeks[5]
Meta-analysis of 27 trials, 20152,569 people with diabetes, high blood fats or high blood pressureNo serious adverse reaction was reported; the authors rate study quality as limited[6]
Diabetes trial, 200858 patients in the berberine and add-on groups20 of 58 (34.5%) reported digestive adverse events; 14 needed a dose reduction[2]

Most trials in these reviews were run in China and enrolled people with metabolic conditions.[4][6] The hypoglycemia estimate came from two trials with events (186 participants); seven other trials reported no events in either group. Evidence certainty for this outcome was very low, so the result does not establish that berberine cannot cause hypoglycemia.[4]

Is berberine bad for the kidneys?

  • What was measured. A 2021 meta-analysis of 46 trials in type 2 diabetes reported serum creatinine and blood urea nitrogen, two routine kidney blood tests, from some trials.[7] These data do not establish long-term kidney safety or safety in people with kidney disease.[7]
  • One small study. In 12 women with polycystic ovary syndrome who took a phospholipid form of berberine for 60 days, liver and kidney blood tests did not change significantly.[8]
  • What is missing. None of the studies cited here was designed to test kidney safety in people with kidney disease. If you have kidney disease, discuss berberine with your clinician first.

Who should be careful

  • Pregnancy, breastfeeding and infants. NCCIH: "Exposure to berberine has been linked to a harmful buildup of bilirubin in infants, which can cause brain damage. Therefore, berberine is likely to be unsafe for infants and may also be unsafe for use during pregnancy or while breastfeeding because of possible effects on the fetus or infant."[1]
  • Medicines. NCCIH: "Berberine may interact with medicines. For example, it has been shown to interact with cyclosporine, a drug used to prevent rejection of transplanted organs."[1] See berberine drug interactions.
  • Diabetes medicines. Trials measured berberine's effect on blood sugar, so anyone taking glucose-lowering medicines should discuss it with their clinician.[2][4]

Information, not a prescription. Do not start, stop or combine supplements or medicines on your own.

More about berberine

Sources

  1. NCCIH. Berberine and Weight Loss: What You Need To Know. Last updated November 2023. https://www.nccih.nih.gov/health/berberine-and-weight-loss-what-you-need-to-know ↩
  2. Yin J et al. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism, 2008;57:712–717. https://doi.org/10.1016/j.metabol.2008.01.013 ↩
  3. Li Z et al. Berberine and health outcomes: an umbrella review. Phytotherapy Research, 2023;37(5):2051–2066. https://doi.org/10.1002/ptr.7806 ↩
  4. Xie W et al. Glucose-lowering effect of berberine on type 2 diabetes: a systematic review and meta-analysis. Frontiers in Pharmacology, 2022;13:1015045. https://doi.org/10.3389/fphar.2022.1015045 ↩
  5. Nie Q et al. The clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease: a meta-analysis and systematic review. Journal of Translational Medicine, 2024;22:225. https://doi.org/10.1186/s12967-024-05011-2 ↩
  6. Lan J et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. Journal of Ethnopharmacology, 2015;161:69–81. https://doi.org/10.1016/j.jep.2014.09.049 ↩
  7. Guo J et al. The effect of berberine on metabolic profiles in type 2 diabetic patients: a systematic review and meta-analysis of randomized controlled trials. Oxidative Medicine and Cellular Longevity, 2021:2074610. https://doi.org/10.1155/2021/2074610 ↩
  8. Rondanelli M et al. Berberine phospholipid is an effective insulin sensitizer and improves metabolic and hormonal disorders in women with polycystic ovary syndrome. Nutrients, 2021;13(10):3665. https://doi.org/10.3390/nu13103665 ↩

You may quote, republish or translate this article under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/): credit "Verateca", link to this page and indicate changes, including translations. Quotes from NIH, FDA and other sources, label texts and prices are not covered by this license.